Roivant’s upcoming data readouts could move stock higher, says Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen notes that when Roivant Sciences (ROIV) announced the new "Vant" deal with Pfizer (PFE) on December 1, the company said that the induction data would come in about three to seven weeks. Chen expects the induction data to be competitive and support a positive readout for the final results, she noted, adding that data readouts that could move Roivant shares higher include this Phase 2b study in patients with moderate to severe ulcerative colitis, or UC, as well as VTAMA topline Phase 3 data for atopic dermatitis, data with Immunovant (IMVT) from their Phase 1 study for a next generation anti-FcRn and data on brepocitinib for systemic lupus erythematosus. The analyst, who thinks the peak sales potential of the rest of Roivant’s pipeline is underappreciated and contends that upwards earnings estimate revisions could drive the stock higher, has an Overweight rating and $15 price target on the shares.